mScarlet/LUC Reporter Cell Line - NCI-H358

NCI-H358 is a human non-small cell lung cancer (NSCLC) cell line established from a bronchioalveolar carcinoma of the lung and is widely used in studies of lung cancer biology, oncogenic signaling, and therapeutic development. The cell line is characterized by the presence of a KRAS mutation and the absence of functional TP53 expression, making it a valuable model for investigating molecular mechanisms that drive tumor progression and therapeutic resistance in KRAS-driven lung cancers. NCI-H358 cells exhibit epithelial morphology and have been extensively utilized in research focused on cell proliferation, apoptosis, metastasis, and targeted treatment strategies. The mScarlet/LUC Reporter Cell Line - NCI-H358 is generated through stable integration of the red fluorescent protein mScarlet and firefly luciferase (LUC) reporter genes into parental NCI-H358 cells. This dual-reporter system enables sensitive fluorescence imaging and quantitative bioluminescence monitoring while preserving the biological characteristics and tumorigenic properties of the original cell line.

The NCI-H358-mScarlet/LUC reporter cell line is broadly employed in lung cancer research for dynamic assessment of tumor growth, metastatic dissemination, and therapeutic response in both in vitro and in vivo settings. Luciferase expression enables non-invasive, longitudinal monitoring of tumor burden through bioluminescence imaging, allowing real-time evaluation of disease progression and treatment efficacy in xenograft models. Meanwhile, mScarlet expression provides bright and stable red fluorescence for high-resolution visualization of cellular morphology, proliferation, migration, invasion, and tissue localization. This model is particularly valuable for evaluating KRAS-targeted therapies, combination treatment strategies, and novel anti-cancer agents designed to overcome therapeutic resistance in NSCLC. In addition, the dual-reporter platform supports mechanistic studies of oncogenic signaling networks, tumor–microenvironment interactions, epithelial–mesenchymal transition, and metastatic processes. With stable reporter expression and robust imaging performance, the NCI-H358-mScarlet/LUC cell line serves as a reliable and reproducible tool for preclinical drug discovery and translational research in KRAS-driven non-small cell lung cancer.